Skip to content
Medical Health Aged Care, Women

The silent crisis no one talks about: ‘On The Down Low’ podcast returns to raise awareness of one of Australia’s fastest growing women’s cancers

Australia New Zealand Gynaecological Oncology Group (ANZGOG) 3 mins read

MEDIA RELEASE 
Thursday 18 September 2025  

The silent crisis no one talks about: ‘On The Down Low’ podcast returns to raise awareness of one of Australia’s fastest growing women’s cancers 

Uterine cancers (including endometrial cancer) are the fastest growing women’s cancer in Australia, yet they remain largely unknown, underfunded, and under-researched. Each year, close to 3,500 women are diagnosed and tragically close to 800 women lose their lifei. Projections indicate this is significantly on the rise with more than 74,000 new cases and 8,900 deaths in the next decade¹. 

To address the silent crisis for women that is not being talked about, the Australia New Zealand Gynaecological Oncology Group (ANZGOG), the peak national gynaecological cancer research organisation, is dedicating Season 2 of its award-winning podcast On The Down Low – Speaking Up About Gynaecological Cancer to uterine cancers, the most common type of gynaecological cancer. 

Hosted by journalist Alison Dance, the six-part series blends raw lived-experience stories with expert medical insights, covering symptoms, diagnosis, treatment, survivorship and advocacy. Each episode encourages women to speak up, ask questions, and explore options for better outcomes—while providing hope for those who, unlike with other cancers, often lack a community to turn to. 

Although uterine cancers have traditionally been diagnosed in mature women, incidence rates are now rising sharply, particularly among women aged 30 to 50, said Professor Alison Brand AM, ANZGOG Director, Research Advisory Committee. 

“Through honest and intimate conversations, we are breaking the silence, shining a light on this urgent issue, and raising awareness of a disease that demands greater knowledge, support, and funding,” Ms Brand said. 

About Uterine Cancers: 

  • Uterine cancer incidence has doubled over the past 20 years and continues to rise, increasingly affecting women aged 30–50. 

  • Women in regional, remote, and rural areas, women from lower socioeconomic backgrounds, and Aboriginal and Torres Strait Islander women face higher incidence and mortality rates. 

  • Unlike breast, ovarian, blood or lung cancers, there is no dedicated support organisation for uterine cancer, leaving close to 3,500 women expected to be diagnosed this year without comprehensive survivorship and supportive care. 

  • By sharing lived experiences and expert knowledge, the podcast addresses this critical gap and highlights the urgent need for research, advocacy, and systemic change. 

‘On The Down Low’ Season 2: Episode overview and launch dates: 

  • S2.E1: Prevention, Risk and Early Diagnosis (from 18 Sept) – Understanding early warning signs, risk factors, and genetic predispositions 

  • S2.E2: Surgery and Fertility Considerations (from 24 Sept) – Exploring surgical options and fertility-sparing treatments. 

  • S2.E3: Research, Treatment and Epidemiology (from 1 Oct) – Emerging therapies, clinical trials, and rising incidence trends. 

  • S2.E4: Challenges of Rare Uterine Cancers (from 8 Oct) – Highlighting rare subtypes, misdiagnosis, and gaps in research. 

  • S2.E5: Survivorship and Rehabilitation (from 15 Oct) – Addressing physical, emotional, and identity recovery, alongside tailored support needs. 

  • S2.E6: Advocacy: What Women Need to Know (from 22 Oct) – Amplifying patient voices, tackling stigma, and driving policy and funding reform. 

Season 2 is produced by ANZGOG, with the generous support of GSK and Eisai. Listen via Apple Podcasts [link] and Spotify [link]. 

Help Break the Silence: By listening, sharing, and starting conversations about uterine cancers, you can help raise awareness, advocate for equitable support, and drive urgently needed change. Learn more at anzgog.org.au.  

Content Warning: This podcast contains personal stories. It is not a substitute for professional medical advice. If you are concerned about your health, contact a healthcare professional or the Cancer Council Information Line on 13 11 20.  

#OnTheDownLowPodcast #UterineCancer #EndometrialCancer #GynaecologicalCancer  

ENDS 

 

About us:
 

About Australia New Zealand Gynaecological Oncology Group (ANZGOG):  

ANZGOG is the peak national gynaecological cancer research organisation in Australia and New Zealand. We foster and lead innovative, world-class multidisciplinary research to improve outcomes and quality of life for everyone with a lived experience of gynaecological cancer.  

Our vision is clear: Advancing research, saving lives. 

For over 26 years, ANZGOG has enabled over 60 clinical trials across all types of gynaecological cancer, involving more than 4,500 patients. These trials are delivered through over 80 hospital sites, supported by both local and global research collaborations. Our growing network includes over 1,500 members across clinical, allied health, and pure research disciplines—alongside community representatives who ensure the voices of women with lived experience are at the centre of everything we do. 


Contact details:

For media interviews or more information, please contact: Monique Cerreto: T: 0416 282 464, E: [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 10/12/2025
  • 16:03
Ramsay Health Care

Ramsay Health Care makes landmark Australian investment in robotic surgical technology

Ramsay Health Care has made one of Australia’s largest single purchases of robotic surgical systems, with 12 new Stryker Mako robots set to be delivered to hospitals across the country over the next three months. The investment strengthens Ramsay’s commitment to modern, innovative health care options that support excellent patient outcomes.Ramsay Health Care’s Chief Operating Officer, Stuart Winters, said Ramsay has a long history of investing in innovation that delivers clear value for patients, clinicians and the broader system.“This investment means more patients, in more communities, will benefit from world-class surgical technology designed to support more personalised care, improved accuracy,…

  • Contains:
  • Finance Investment, Women
  • 10/12/2025
  • 11:26
Monash University

New Australian study shows devastating impact of coerced business debt

A pioneering national study, conducted by a Monash University expert in collaboration with consumer advocates, has shed light on the hidden toll of coerced business debt, revealing how business structures are being weaponised to perpetrate financial abuse, resulting in long-term economic hardship. The study – led by Associate Professor Vivien Chen of Monash Business School and Jasmine Opdam, Senior Policy and Advocacy Officer at Redfern Legal Centre’s Financial Abuse Service NSW, and conducted in collaboration with the Economic Abuse Reference Group – is the first national study of its kind. It highlights how women in heterosexual relationships are disproportionately the…

  • Medical Health Aged Care
  • 10/12/2025
  • 09:35
Royal Australian College of GPs

Victorian Opposition’s free MenB vaccine commitment ‘will save young lives’: GPs

The Royal Australian College of GPs (RACGP) has welcomed a commitment from the Victorian Liberals and Nationals to provide free vaccinations against deadly meningococcal Binfections. Meningococcal Binfections can cause meningitis (brain inflammation) or septicaemia (blood poisoning) resulting in rapid death or disability including brain damage and limb loss. Victoria has recorded 14 cases of meningococcal B this year. RACGP Victoria again called for the State Government to match other jurisdictions by providing free vaccines to at-risk groups following the passing of 16-year-old Levi Syer, who died shortly after developing symptoms of the deadly bacterial infection. While the meningococcal ACWY vaccine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.